Immuno-Oncology Research

Immuno-oncology research is providing the foundation for the development of more effective cancer therapies. To support these studies, we are focused on providing the highest quality reagents to simplify and advance your research. From proteins and antibodies to single and multianalyte immunoassays, our products undergo extensive in-house validation to ensure performance, consistency, and specificity, so you can have confidence in your results from one experiment to the next.

Immune Checkpoint Targets

Immune checkpoint molecules can either promote or inhibit immune cell functions. Ligand binding to stimulatory receptors promotes immune cell activation, while ligand binding to inhibitory receptors suppresses immune cell activation.

Tumor cells frequently exploit immune checkpoint pathways by up-regulating the expression of ligands that bind to inhibitory receptors, allowing them to evade immune detection. To prevent this, researchers have targeted immune checkpoint molecules for cancer immunotherapy using either agonists of immune cell stimulatory receptors to drive immune cell activation, or antagonists of inhibitory receptors to prevent down-regulation of anti-tumor immune responses. Use the links below to browse our selection of products for immune checkpoint research.

Immune Cell Phenotyping in the Tumor Microenvironment

The tumor microenvironment (TME) is a complex network of different cell types that can either suppress or promote tumor growth. Use the links below to find the markers that are commonly used to distinguish different immune cell types or cell type-specific subsets in the tumor microenvironment.

Cell-Mediated Mechanisms of Immunosuppression in the Tumor Microenvironment

Regulatory T cells, myeloid-derived suppressor cells, and tumor-associated M2 macrophages are immune cells with immunosuppressive properties that are thought to play key roles in inhibiting anti-tumor immune responses. Explore the interactive pathways linked below to learn about the different mechanisms that these cell types use to negatively regulate anti-tumor immune responses.

Cancer Signaling Pathways

Signaling pathways that regulate cell survival, proliferation, and growth are frequently altered in tumor cells and can contribute to immune suppression and resistance to immune checkpoint blockade strategies. View these pathways to see how they may promote tumor escape and gain a better understanding of why simultaneous blockade of these pathways is being investigated to improve the efficacy of immune checkpoint therapies.

Featured Research & Product Areas

Featured Resources